目的 探讨秋水仙碱对稳定型冠心病（SCAD）的辅助治疗作用及改善预后的效果。方法 选取2022-01至2023-07武警四川总队医院收治的SCAD患者100例,按治疗方法不同,分为秋水仙碱组和对照组,每组50例。对照组进行常规治疗（如他汀类、抗血小板药物等）,秋水仙碱组在常规治疗的基础上加用秋水仙碱,两组治疗时间均为12个月。治疗后,对两组患者生存率、治疗效果、心血管不良事件（MACE）发生率、生活质量（QOL）、血清中炎症因子白细胞介素-6（IL-6）与超敏C反应蛋白（hs-CRP）水平进行比较。结果 治疗后,秋水仙碱组总有效率为91.84%、简明生活量表SF-36评分为（84.13±14.13）分,虽高于对照组的85.11%、（82.47±12.64）分,但差异无统计学意义。治疗后,秋水仙碱组MACE发生率为6.00%,较对照组20.00%显著降低,差异有统计学意义（P<0.05）;血清中IL-6、hs-CRP含量分别为（1.99±0.78）ng/L、（2.04±0.98）mg/L,明显低于对照组[（2.48±1.32）ng/L、（4.30±1.21）mg/L],差异有统计学意义（P<0.05）。结论 秋水仙碱对SCAD的辅助治疗效果明显,且可降低SCAD患者MACE发生率及血清中IL-6、hs-CRP水平。
Abstract
Objective To explore the adjuvant therapeutic effect and prognostic improvement of colchicine for stable coronary artery disease （SCAD）. Methods A total of 100 SCAD patients admitted to Sichuan Provincial Corps Hospital of Chinese People’s Armed Police Force from January 2022 to July 2023 were selected. According to different treatment methods,they were divided into a colchicine group and a control group, with 50 cases in each group. The control group received conventional treatment （such as statins,antiserum plate drugs,etc.）,while the colchicine group received colchicine on the basis of conventional treatment. Both groups underwent a 12-month treatment period. After treatment,the survival rate, treatment effect,major adverse cardiovascular events (MACE), quality of life (QOL), and levels of serum inflammatory factor, such as interleukin-6 (IL-6）and high-sensitivity C-reactive protein （hs-CRP), were compared between the two groups. Results After treatment, the total effective rate of the colchicine group was 91.84% and the score of the Short Form 36 Health Survey（SF-36） was （84.13±14.13）, which was higher than 85.11% and （82.47 ± 12.64）of the control group, but the difference were not statistically significant （P> 0.05）. After treatment, the incidence of MACE of the colchicine group was 6.00%,which was significantly lower than of the control group ( 20.00% ), and the difference was statistically significant（P< 0.05）; the levels of IL-6 and hs-CRP in the serum were （1.99 ± 0.78） ng/L and （2.04 ± 0.98） mg/L, respectively, which were significantly lower than those of the control group （2.48 ± 1.32） ng/L and （4.30 ± 1.21） mg/L, and the difference was statistically significant （P< 0.05）. Conclusions Colchicine has a significant adjuvant therapeutic effect on SCAD and can reduce the incidence of MACE and the levels of IL-6 and hs-CRP in the serum of SCAD patients.
关键词
秋水仙碱 /
稳定型冠心病 /
辅助治疗 /
心血管不良事件 /
炎症因子
Key words
colchicine /
stable coronary artery disease /
adjuvant treatment /
major adverse cardiovascular events /
inflammatory factor
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 周鹭, 崔红燕, 李浩然, 等. 小剂量利伐沙班联合阿司匹林防治动脉粥样硬化疾病的研究进展[J]. 临床心血管病杂志, 2022, 38(10): 780-785.
[2] 王帆, 刘宗武. 血清髓过氧化物酶作为稳定型冠心病标志物的可行性[J]. 中国老年学杂志, 2023, 43(23): 5633-5636.
[3] 中华心血管病杂志(网络版)编辑委员会. 动脉粥样硬化斑块的筛查与临床管理专家共识[J]. 中华心血管病杂志(网络版), 2022, 5(1): 1-13.
[4] 吉蓉, 寿锡凌. 秋水仙碱在冠状动脉粥样硬化性心脏病防治中的研究进展与争议[J]. 心血管病学进展, 2022, 43(1):60-63.
[5] 刘学谦, 范丽花, 陈赟虎, 等. 不同抗炎药物治疗冠心病有效性和安全性的系统评价[J]. 中西医结合心脑血管病杂志, 2024, 22(15): 2799-2807.
[6] 张颖, 杨琳, 李军梅, 等. 心血管疾病治疗中的中西药药物相互作用[J]. 中国中药杂志, 2022, 47(19): 5121-5130.
[7] 秦宇辰, 秦婴逸, 郭威,等. 海军航空兵某部官兵生命质量现状及其影响因素调查[J]. 武警医学, 2023, 34(7): 566-571,576.
[8] 窦芳, 王海霞, 董钰. 曲美他嗪联合阿托伐他汀治疗冠心病不稳定型心绞痛的效果[J]. 临床医学, 2024, 44(11): 105-107.
[9] 庄文文, 杜明亮, 惠慧, 等. 冠心病抗炎治疗的临床研究进展[J]. 心血管病学进展, 2024, 45(3): 266-271.
[10] Virani S S, Newby L K, Arnold S V, et al. 2023 AHA/ACC/ACCP/ASPC/ NLA/ PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American college of cardiology joint committee on clinical practice guidelines[J]. J Am Coll Cardiol, 2023, 82(9): 833-955.
[11] Deftereos S G, Beerkens F J, Shah B, et al. Colchicine in Cardiovascular Disease: In-Depth Review[J]. Circulation, 2022, 145(1):61-78.
[12] Whayne T F.Inflammation may be the future of cardiovascular risk reduction: does colchicine have a current indication[J]. Am J Cardiovasc Drugs, 2021, 21(1):1-10.
[13] Xia M, Yang X, Qian C.Meta-analysis evaluating the utility of colchicine in secondary prevention of coronary artery disease[J]. Am J Cardiol, 2021, 140:33-38.
[14] 常书福. 冠心病药物治疗进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 405-408.
[15] Xiang Z, Yang J, Yang J, et al. Efficacy and safety of colchicine for secondary prevention of coronary heart disease: a systematic review and meta-analysis[J]. Intern Emerg Med, 2021, 16(2): 487-496.
[16] Vaidya K, Arnott C, Martínez G J, et al. Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a ct coronary angiography study[J]. JACC Cardiovasc Imaging, 2018, 11(2 Pt 2): 305-316.
[17] 俞赟丰, 周曼丽, 罗晓欣, 等. 秋水仙碱治疗冠心病的Meta分析和试验序贯分析[J]. 中国循环杂志, 2021, 36(7): 659-666.
[18] 权青云, 赵晓娟, 张愉, 等. 老年高血压病患者血清pro-BNP及hs-CRP水平与认知功能的相关性[J]. 武警医学, 2022, 33(1): 57-59.
[19] 郑黎黎, 衡衍, 蒲丹岚, 等. 康复疗法在部队高脂血症患者中的应用及其对巨噬细胞肿瘤坏死因子-α、白细胞介素-6的影响[J]. 武警医学, 2024, 35(4): 286-289.
[20] Fiolet A T, Silvis M J, Opstal T S, et al. Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein[J].PloS one,2020, 15(8): e0237665.
PDF(2111 KB)
